• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic-Based Point-of-Care Antibody Testing.东京新冠肺炎疫情的地理概况:基于基层医疗诊所即时检验抗体检测的分析
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720942695. doi: 10.1177/2150132720942695.
2
Epidemiology of SARS-CoV-2 antibodies among firefighters/paramedics of a US fire department: a cross-sectional study.美国消防部门消防员/护理人员中 SARS-CoV-2 抗体的流行病学:一项横断面研究。
Occup Environ Med. 2020 Dec;77(12):857-861. doi: 10.1136/oemed-2020-106676. Epub 2020 Aug 6.
3
Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG.用于检测抗 SARS-CoV-2 IgG 的本土 IgG ELISA 的开发。
Indian J Med Res. 2020 May;151(5):444-449. doi: 10.4103/ijmr.IJMR_2232_20.
4
SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.SARS-CoV-2 血清流行率在肿瘤学医疗保健专业人员和癌症患者在三级保健中心在 COVID-19 大流行期间。
ESMO Open. 2020 Sep;5(5):e000889. doi: 10.1136/esmoopen-2020-000889.
5
Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho.雅培Architect SARS-CoV-2 IgG检测法的性能特征及爱达荷州博伊西市的血清阳性率
J Clin Microbiol. 2020 Jul 23;58(8). doi: 10.1128/JCM.00941-20.
6
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.西班牙 2020 年人群血清流行病学研究(ENE-COVID):全国范围内基于人群的血清流行病学研究。
Lancet. 2020 Aug 22;396(10250):535-544. doi: 10.1016/S0140-6736(20)31483-5. Epub 2020 Jul 6.
7
Seroprevalence of SARS-Cov-2 in 646 professionals at the Rothschild Foundation Hospital (ProSeCoV study).罗斯柴尔德基金会医院646名专业人员中SARS-CoV-2的血清阳性率(ProSeCoV研究)。
Anaesth Crit Care Pain Med. 2020 Oct;39(5):595-596. doi: 10.1016/j.accpm.2020.08.003. Epub 2020 Aug 27.
8
IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea.韩国大邱市无冠状病毒疾病感染史个体的 COVID-19 IgG 血清阳性率。
J Korean Med Sci. 2020 Jul 27;35(29):e269. doi: 10.3346/jkms.2020.35.e269.
9
Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020.2020 年 5 月至 6 月印度全国血清学调查的 SARS-CoV-2 感染流行率。
Indian J Med Res. 2020;152(1 & 2):48-60. doi: 10.4103/ijmr.IJMR_3290_20.
10
Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak.新型冠状病毒(SARS-CoV-2)感染的血清学检测在 COVID-19 疫情期间的诊断评估。
Eur J Clin Microbiol Infect Dis. 2020 Dec;39(12):2271-2277. doi: 10.1007/s10096-020-03978-6. Epub 2020 Jul 17.

引用本文的文献

1
Ten pressure points in primary care during COVID-19: findings from an international narrative review.新冠疫情期间初级保健中的十个关键点:一项国际叙述性综述的结果
BMC Prim Care. 2025 Jan 24;26(1):19. doi: 10.1186/s12875-024-02640-w.
2
Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic.血清流行率和 SARS-CoV-2 在普通人群中的入侵:大流行第一年的范围综述。
PLoS One. 2023 Apr 19;18(4):e0269104. doi: 10.1371/journal.pone.0269104. eCollection 2023.
3
Population-based repeat cross-sectional seroprevalence survey of SARS-CoV-2 IgG antibodies in Pimpri Chinchwad Municipal Corporation Area, Maharashtra, India.印度马哈拉施特拉邦皮姆普里-钦奇沃德市政公司区域基于人群的SARS-CoV-2 IgG抗体重复横断面血清流行率调查。
J Family Med Prim Care. 2022 Jun;11(6):2789-2793. doi: 10.4103/jfmpc.jfmpc_1869_21. Epub 2022 Jun 30.
4
Seropositivity for SARS-CoV-2 in a General Population: How Specific Is the Diagnostic?普通人群中SARS-CoV-2血清阳性:诊断的特异性如何?
J Epidemiol. 2023 Jan 5;33(1):62. doi: 10.2188/jea.JE20220151. Epub 2022 Nov 11.
5
High Level of SARS-CoV-2 Infection in Young Population Is a Predictor for Peak Incidence.年轻人群中高感染水平的新冠病毒是发病率峰值的一个预测指标。
Front Microbiol. 2022 May 31;13:891646. doi: 10.3389/fmicb.2022.891646. eCollection 2022.
6
SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis.全球范围内 SARS-CoV-2 血清流行率:一项更新的系统评价和荟萃分析。
Eur J Med Res. 2022 Jun 2;27(1):81. doi: 10.1186/s40001-022-00710-2.
7
Serologic Survey of IgG Against SARS-CoV-2 Among Hospital Visitors Without a History of SARS-CoV-2 Infection in Tokyo, 2020-2021.2020-2021 年东京无 SARS-CoV-2 感染史的医院访客中针对 SARS-CoV-2 的 IgG 血清学调查。
J Epidemiol. 2022 Feb 5;32(2):105-111. doi: 10.2188/jea.JE20210324. Epub 2021 Dec 17.
8
Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study.日本福岛县农村地区医院工作人员中 SARS-CoV-2 抗体的血清流行率:一项历史队列研究。
Int Immunopharmacol. 2021 Sep;98:107884. doi: 10.1016/j.intimp.2021.107884. Epub 2021 Jun 14.
9
Combination of a SARS-CoV-2 IgG Assay and RT-PCR for Improved COVID-19 Diagnosis.SARS-CoV-2 IgG 抗体检测与 RT-PCR 联合应用以提高 COVID-19 诊断准确性。
Ann Lab Med. 2021 Nov 1;41(6):568-576. doi: 10.3343/alm.2021.41.6.568.
10
SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study.魁北克省献血者中 SARS-CoV-2 的血清流行率,以及与血清阳性相关症状的分析:一项嵌套病例对照研究。
Can J Public Health. 2021 Aug;112(4):576-586. doi: 10.17269/s41997-021-00531-6. Epub 2021 May 17.

本文引用的文献

1
COVID-19 antibody seroprevalence in Santa Clara County, California.加利福尼亚州圣克拉拉县的新冠病毒抗体血清流行率。
Int J Epidemiol. 2021 May 17;50(2):410-419. doi: 10.1093/ije/dyab010.
2
Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in Japan.日本针对新冠病毒群体免疫开展社区即时抗体检测的挑战。
QJM. 2020 Nov 1;113(11):785-786. doi: 10.1093/qjmed/hcaa182.
3
Herd Immunity: Understanding COVID-19.群体免疫:了解 COVID-19。
Immunity. 2020 May 19;52(5):737-741. doi: 10.1016/j.immuni.2020.04.012.
4
Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020.2020 年 4 月 10 日至 11 日,加利福尼亚州洛杉矶县成年人中 SARS-CoV-2 特异性抗体的血清流行率。
JAMA. 2020 Jun 16;323(23):2425-2427. doi: 10.1001/jama.2020.8279.
5
Serology assays to manage COVID-19.用于管理新冠病毒病的血清学检测
Science. 2020 Jun 5;368(6495):1060-1061. doi: 10.1126/science.abc1227. Epub 2020 May 15.
6
Organising community primary care in the age of COVID-19: challenges in disadvantaged areas.在新冠疫情时代组织社区初级医疗保健:贫困地区面临的挑战。
Lancet Public Health. 2020 Jun;5(6):e313. doi: 10.1016/S2468-2667(20)30115-8. Epub 2020 May 13.
7
Roles and challenges of primary care physicians facing a dual outbreak of COVID-19 and dengue in Singapore.新加坡基层医疗医生在应对新冠疫情和登革热双重疫情时所扮演的角色及面临的挑战。
Fam Pract. 2020 Sep 5;37(4):578-579. doi: 10.1093/fampra/cmaa047.
8
Antibody responses to SARS-CoV-2 in patients with COVID-19.新型冠状病毒肺炎(COVID-19)患者的 SARS-CoV-2 抗体反应。
Nat Med. 2020 Jun;26(6):845-848. doi: 10.1038/s41591-020-0897-1. Epub 2020 Apr 29.
9
Enhancing the triage and cohort of patients in public primary care clinics in response to the coronavirus disease 2019 (COVID-19) in Hong Kong: an experience from a hospital cluster.香港应对2019冠状病毒病(COVID-19)时加强公立基层医疗诊所患者的分流与分组:医院联网的经验
BJGP Open. 2020 Jun 23;4(2). doi: 10.3399/bjgpopen20X101073. Print 2020.
10
Covid-19: how Japan squandered its early jump on the pandemic.新冠疫情:日本如何错失在疫情初期取得的先机。
BMJ. 2020 Apr 24;369:m1625. doi: 10.1136/bmj.m1625.

东京新冠肺炎疫情的地理概况:基于基层医疗诊所即时检验抗体检测的分析

Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic-Based Point-of-Care Antibody Testing.

作者信息

Takita Morihito, Matsumura Tomoko, Yamamoto Kana, Yamashita Erika, Hosoda Kazutaka, Hamaki Tamae, Kusumi Eiji

机构信息

Navitas Clinic Tachikawa, Tachikawa, Tokyo, Japan.

Navitas Clinic Shinjuku, Shinjuku, Tokyo, Japan.

出版信息

J Prim Care Community Health. 2020 Jan-Dec;11:2150132720942695. doi: 10.1177/2150132720942695.

DOI:10.1177/2150132720942695
PMID:32674696
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7370565/
Abstract

The primary care clinic plays a major role in triage for coronavirus disease 2019 (COVID-19), where seroprevalence in the setting of primary care clinic remains less clear. As a point-of-care immunodiagnostic test for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the serosurvey represents an alternative to the polymerase chain reaction (PCR) test to measure the magnitude of COVID-19 outbreak in the communities lacking sufficient diagnostic capability for PCR testing. We assessed seropositivity for the SARS-CoV-2 IgG between April 21 and May 20, 2020, at 2 primary care clinics in Tokyo, Japan. The overall positive percentage of SARS-CoV-2 IgG was 3.83% (95% confidence interval [CI]: 2.76-5.16) for the entire cohort (n = 1071). The 23 special wards of central Tokyo exhibited a significantly higher prevalence compared with the other areas of Tokyo after classification by residence ( = .02, 4.68% [3.08-6.79] vs 1.83 [0.68-3.95] in central and suburban Tokyo, respectively). In central Tokyo, the southern area showed the highest seroprevalence compared with the other areas (7.92% [3.48-15.01]), corresponding to the cumulative number of confirmed COVID-19 patients by PCR test reported by the Tokyo Metropolitan Government. The seroprevalence surveyed in this study was too low for herd immunity, suggesting the need for robust disease control and prevention. A regional-level approach, rather than state- or prefectural-level, could be of importance in ascertaining detailed profiles of the COVID-19 outbreak.

摘要

基层医疗诊所在2019冠状病毒病(COVID-19)的分诊中发挥着重要作用,而基层医疗诊所环境中的血清流行率仍不太明确。作为针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的即时免疫诊断检测,血清学调查是聚合酶链反应(PCR)检测的一种替代方法,用于在缺乏足够PCR检测诊断能力的社区中衡量COVID-19疫情的规模。我们于2020年4月21日至5月20日在日本东京的两家基层医疗诊所评估了SARS-CoV-2 IgG的血清阳性率。整个队列(n = 1071)中SARS-CoV-2 IgG的总体阳性率为3.83%(95%置信区间[CI]:2.76 - 5.16)。按居住地分类后,东京市中心的23个特别区的患病率明显高于东京其他地区(P = 0.02,分别为4.68%[3.08 - 6.79]和东京市中心及郊区的1.83%[0.68 - 3.95])。在东京市中心,南部地区的血清流行率高于其他地区(7.92%[3.48 - 15.01]),这与东京都政府报告的通过PCR检测确诊的COVID-19患者累计数量相对应。本研究中调查的血清流行率过低,无法实现群体免疫,这表明需要强有力的疾病控制和预防措施。在确定COVID-19疫情的详细情况时,采用区域层面而非国家或县级层面的方法可能很重要。